Accumulation of JAK activation loop phosphorylation is linked to type I JAK inhibitor withdrawal syndrome in myelofibrosis

Treatment of patients with myelofibrosis with the type I JAK (Janus kinase) inhibitor ruxolitinib paradoxically induces JAK2 activation loop phosphorylation and is associated with a life-threatening cytokine-rebound syndrome if rapidly withdrawn. We developed a time-dependent assay to mimic ruxoliti...

Descripción completa

Detalles Bibliográficos
Autores principales: Tvorogov, Denis, Thomas, Daniel, Liau, Nicholas P. D., Dottore, Mara, Barry, Emma F., Lathi, Maya, Kan, Winnie L., Hercus, Timothy R., Stomski, Frank, Hughes, Timothy P., Tergaonkar, Vinay, Parker, Michael W., Ross, David M., Majeti, Ravindra, Babon, Jeffrey J., Lopez, Angel F.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Association for the Advancement of Science 2018
Materias:
Research Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6261652/
https://www.ncbi.nlm.nih.gov/pubmed/30498775
http://dx.doi.org/10.1126/sciadv.aat3834

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6261652/
https://www.ncbi.nlm.nih.gov/pubmed/30498775
http://dx.doi.org/10.1126/sciadv.aat3834

Ejemplares similares